Antibodies being used as a T-cell targeting system to wipe out cancer cells

Nanolive’s automated microscope, the CX-A, allows scientists to monitor dynamic interactions between immune cells and cancer cells at the population level, unperturbed, and with zero phototoxicity involved. Here, the CX-A was used to visualize whether the addition of bispecific antibodies enhanced the cancer-killing ability of cytotoxic T-Cells. Images were taken every four and a half minutes, for twenty hours.
Cytotoxic T-cells are powerful effector cells capable of killing target cells bearing an appropriate antigenic complex (peptide–MHC), which is recognized by their T-cell receptor (TCR). Most T-cells are however unable to recognize and kill tumor cells, because of the lack of tumor-specificity of their TCR.

By using bispecific antibodies targeting a tumor-associated antigen (TAA) on the cancer cells, and CD3 on the T-cells, it is possible to redirect and activate any circulating T-cells against tumor cells independently of the specificity of their TCR. Thanks to the bridging action of such TAAxCD3 bsAb, T-cells are brought in close proximity of the target cancer cells, leading to subsequent T-cell activation and T-cell–mediated killing of the tumor cells.

For more information on T-cell redirecting κλ-bodies, please visit Light Chain Bioscience.

Read our latest news

Nanolive – our story

Nanolive – our story

Nanolive Nanolive delivers breakthrough imaging solutions that combine screening, imaging, and analysis to radically advance how scientists study living cells and provide novel biological insights into the mechanisms of cancer and neurodegenerative diseases. Our...